What This Virus Expert Thinks About mRNA Vaccine Candidates for COVID-19

Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) reported incredible efficacy data from a phase 3 trial for their mRNA coronavirus vaccine candidate. This news, paired with the equally impressive data from Moderna (NASDAQ: MRNA) about its candidate that takes a similar approach, inspired much hope around the world and injected optimism into the stock market.

We talked with Dr. Angela Rasmussen, a virologist and Associate Research Scientist at Columbia Center for Infection and Immunity, about what this exciting development means for the world and for investors.

 

Continue reading

Source Fool.com